Senores Pharma ka Naya Funding Plan: ₹95 Crore Aayenge, Subsidiary ko Milega Support!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Senores Pharma ka Naya Funding Plan: ₹95 Crore Aayenge, Subsidiary ko Milega Support!
Overview

Arre suno, Senores Pharma ne ek mast plan banaya hai. Woh log **₹95 Crore** utha rahe hain preferential issue mein warrants dekar. Yeh paisa seedha subsidiary Apnar Pharma ko milega unke working capital needs ke liye.

Toh scene ye hai ki Senores Pharmaceuticals apne promoter aur promoter group ko 11.7 lakh convertible equity warrants dega. Har warrant se woh ₹812 ke price pe ek equity share subscribe kar sakte hain. Is poore deal se company ka target hai ₹95 Crore fund raise karna.

Subsidiary ke liye Paisa

Yeh jo naya paisa aa raha hai na, yeh seedha Apnar Pharma Private Limited ko support karne ke liye hai, jahan Senores Pharma ne recently 75% stake acquire kiya tha. Funds primarily Apnar Pharma ke working capital requirements ke liye use honge. Apnar Pharma ki facility USFDA, UK-MHRA aur Health Canada approved hai, jisse Senores apni manufacturing capabilities aur regulated markets mein access badhana chahta hai.

Financials ka Kya Scene Hai?

Company ne pichhle saalon mein zabardast growth dikhaya hai. FY24 mein revenue 457.0% badh kar ₹2,173 million ho gaya aur net profit 287.9% jump kar ke ₹327 million pahunch gaya. Latest 9 mahino mein (December 2025 tak) bhi revenue 64% upar tha aur profit after tax 105% bada. Full FY25 mein total income ₹410 crore thi.

Thode Risks Bhi Hain

Par bhai, sab kuch itna smooth nahi hai. Profitability margins par pressure dikh raha hai. Operating profit margin FY24 mein 19.4% tha, jo FY23 ke 35.9% se kam hai. Net profit margin bhi 15.2% se 23.9% ho gaya. Company ka debt bhi FY24 mein ₹1 billion (matlab ₹100 Crore) ho gaya hai aur debt-to-equity ratio 0.7 hai. Last 3 saal se ROE 1.64% aur ROCE 3.45% ke aas paas hi hai, jo kafi low hai. Debtor days 225.88 hain, yani clients se paisa collect karne mein time lag raha hai. Aur cash flow from operations toh consistently negative hi raha hai. Plus, Apnar Pharma ka revenue FY25 mein 48% gira tha. Auditors bhi recently change hue hain.

Aage Kya?

Yeh capital infusion ek strategic move hai Apnar Pharma ko integrate karne ke liye. Investors abhi ye dekhenge ki ye warrants kaise convert hote hain aur funds kaise deploy hote hain. Margin pressure aur badhte debt ko manage karna company ke liye critical hoga.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.